Sofie Daelemans
University of Antwerp
7 Papers
6 Citations
Sofie Daelemans is an academic researcher from University of Antwerp. The author has contributed to research in topics: Internal medicine & Bladder cancer. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Thomas Powles,Mark M. Kockx,Alejo Rodriguez-Vida,Ignacio Duran,Simon J. Crabb,Michiel S. van der Heijden,Bernadett Szabados,Albert Font Pous,Gwenaelle Gravis,Urbano Anido Herranz,Andrew Protheroe,Alain Ravaud,Denis Maillet,Maria Jose Mendez,Cristina Suarez,Mark Linch,Aaron Prendergast,Peter A. van Dam,Diana Stanoeva,Sofie Daelemans,Sanjeev Mariathasan,Joy S. Tea,Kelly Mousa,Romain Banchereau,Daniel Castellano +24 more
TL;DR: A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Bernadett Szabados,Mark M. Kockx,Zoe June Assaf,Peter van Dam,Alejo Rodriguez-Vida,Ignacio Duran,Simon J. Crabb,Michiel S. van der Heijden,Albert Font Pous,Gwenaelle Gravis,Urbano Anido Herranz,Andrew Protheroe,Alain Ravaud,Denis Maillet,Maria Jose Mendez,Cristina Sáez,Mark Linch,A Prendergast,Charlotte Tyson,Diana Stanoeva,Sofie Daelemans,Miche Rombouts,Sanjeev Mariathasan,Joy S. Tea,Kelly Mousa,Shrutie Sharma,Alexey Aleshin,Romain Banchereau,Daniel Castellano,Thomas Powles +29 more
TL;DR: The ABACUS trial as mentioned in this paper showed that patients receiving immunotherapy followed by cystectomy have good long-term outcomes, and that certain biological features can predict patients who might have particular benefit from this therapy.
Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases
Raymond L. Barnhill,Raymond L. Barnhill,Peter B. Vermeulen,Sofie Daelemans,Peter A. van Dam,Sergio Roman-Roman,Vincent Servois,Ilse Hurbain,Ilse Hurbain,Ilse Hurbain,Sophie Gardrat,Graça Raposa,Graça Raposa,Graça Raposa,André Nicolas,Rémi Dendale,Gaëlle Pierron,Laurence Desjardins,Nathalie Cassoux,Nathalie Cassoux,Sophie Piperno-Neumann,Pascale Mariani,Claire Lugassy +22 more
- 01 Oct 2018
TL;DR: The frequency of the replacement and desmoplastic HGPs in liver UM metastases resected from living patients, and their potential important prognostic value for UM patients, as in other solid cancers, are reported for the first time.
62
Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
Tim Muilwijk,Murat Akand,Sofie Daelemans,Koen M. Marien,Yannick Waumans,Mark M. Kockx,Loïc Baekelandt,Thomas Van den Broeck,Frank Van der Aa,Thomas Gevaert,Steven Joniau +10 more
TL;DR: Fibroblast activation protein-α (FAP) is a transmembrane peptidase and a surrogate marker for cancerassociated fibroblasts (CAFs) as mentioned in this paper.
Progression of high-risk non-muscle invasive bladder cancer correlates with immune phenotypes and Fibroblast Activation Protein-α (FAP)
Tim Muilwijk,Loïc Baekelandt,Murat Akand,Sofie Daelemans,K. Marien,Yannick Waumans,Peter van Dam,Thomas Van den Broeck,Ben Van Cleynenbreugel,Frank Van der Aa,Thomas Gevaert,Steven Joniau +11 more